论文部分内容阅读
目的观察Her-2/neu过表达的乳腺癌患者对不同辅助化疗方案的敏感性。方法选取2002年5月至2005年8月在我院乳腺中心接受手术且术后辅助化疗的原发性乳腺癌患者Her-2过表达者共134例,分别采用蒽环类或紫杉类方案化疗,中位随访时间38个月,分析她们的临床特征和病理学特征,不同化疗方案对无病生存期的影响。结果Her-2过表达(++、+++)者134例,占27.7%,采用CAF方案化疗者77例,含紫杉类化疗者57例,采用CAF方案复发转移31.2%(24/77),无病生存率68.8%,含紫杉类复发率14.0%(8/57),无病生存率86%,χ2=5.290,P<0.05。结论说明含紫杉类方案术后辅助化疗能够提高Her-2/neu过表达的乳腺癌患者的无病生存期。
Objective To investigate the sensitivity of Her-2 / neu overexpressing breast cancer patients to different adjuvant chemotherapy regimens. Methods A total of 134 patients with Her-2 overexpression in primary breast cancer who underwent surgery and postoperative adjuvant chemotherapy from May 2002 to August 2005 in our hospital were selected. Anthracycline and / Chemotherapy, median follow-up time of 38 months, analysis of their clinical and pathological features, different chemotherapy regimens on disease-free survival. Results There were 134 cases (27.7%) of Her-2 overexpression (++, +++), 77 cases of chemotherapy with CAF regimen, 57 cases of chemotherapy with taxanes, and 31.2% (24/77 ), Disease-free survival rate 68.8%, taxane-containing recurrence rate 14.0% (8/57), disease-free survival rate 86%, χ2 = 5.290, P <0.05. Conclusions The postoperative adjuvant chemotherapy with the taxane-containing regimen increases the disease-free survival of breast cancer patients overexpressing Her-2 / neu.